In addition, it was revealed that this chemical group displays advantages in suppressing hard-to-treat cancers such as TNBC [19,28,35,55,57,66], brain cancer [20,44,50,54,62,63,64,65,74,75], and KRAS-mutant lung cancer [39], but also chemo-resistant cancer cells [58,59,69,70] in preclinical studies, with the possibility of synergizing with established conventional therapies, including radiation [26,39,42,43,59,60,73,88]. This evidence concerns the gene KRAS and cancer.